Sandip Agarwala
Private Equity Investor chez BLUE OWL CAPITAL INC.
Fortune : - $ au 31/03/2024
Profil
Sandip K.
Agarwala has founded CrownWheel Partners LLC in 2013, where he holds the title of Managing Director.
He is currently working as a Director at Tiburio Therapeutics, Inc. since 2018, as well as a Director at Opna-IO LLC and Opna Immuno-Oncology SA. In 2022, he started working as a Managing Director at Blue Owl Capital, Inc. and Blue Owl Credit Advisors LLC.
Mr. Agarwala's former positions include being a Managing Director at Longitude Capital Management Co LLC from 2014 to 2022, a Director at Cydan II, Inc. from 2017 to 2022, and a Director at Endeavor BioMedicines, Inc. and Lexeo Therapeutics, Inc. from 2020 to 2022.
He also held positions as an Independent Director at Talaris Therapeutics, Inc., a Consultant at The Boston Consulting Group, Inc., a Principal at Paul Capital Partners LP and Healthcare Royalty Management LLC, and a Consultant at The Frankel Group Associates LLC.
Additionally, he served as a Vice President at Auven Therapeutics Management LLLP in 2012 and as a Board Observer at Aptinyx, Inc. and Inozyme Pharma, Inc.Mr. Agarwala completed his undergraduate studies at the University of Pennsylvania and obtained an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
-.--% | 17/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Sandip Agarwala
Sociétés | Poste | Début |
---|---|---|
BLUE OWL CAPITAL INC. | Private Equity Investor | 01/02/2022 |
CrownWheel Partners LLC
CrownWheel Partners LLC Financial ConglomeratesFinance CrownWheel Partners LLC engages in the provision of structure financing solutions with healthcare companies, academic institutions, and inventors. It focuses on the monetization of royalty streams, revenue participation, and purchase of structured debt and equity. The company was founded by Sandip K. Agarwala in 2013 and is headquartered in Greenwich, CT. | Chief Executive Officer | 01/01/2013 |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Director/Board Member | - |
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | Director/Board Member | - |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Director/Board Member | 01/12/2018 |
Blue Owl Credit Advisors LLC
Blue Owl Credit Advisors LLC Investment ManagersFinance Blue Owl Credit Advisors LLC (Blue Owl Credit Advisors) is a private equity subsidiary of Blue Owl Capital, Inc founded in 2015 by Douglas Ostrover, Marc Lipschultz and Craig W. Packer. The firm headquartered in New York. | Private Equity Investor | 01/02/2022 |
Anciens postes connus de Sandip Agarwala
Sociétés | Poste | Fin |
---|---|---|
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Director/Board Member | 28/02/2022 |
LEXEO THERAPEUTICS, INC. | Director/Board Member | 28/02/2022 |
Longitude Capital Management Co LLC
Longitude Capital Management Co LLC Investment ManagersFinance Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 28/02/2022 |
░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Sandip Agarwala
University of Pennsylvania | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
APTINYX | Health Technology |
INOZYME PHARMA, INC. | Health Technology |
LEXEO THERAPEUTICS, INC. | Health Technology |
BLUE OWL CAPITAL INC. | Finance |
Entreprise privées | 14 |
---|---|
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Commercial Services |
Paul Capital Partners LP
Paul Capital Partners LP Investment ManagersFinance Founded in 1991 by Philip Paul, Paul Capital Partners LP is a private equity firm located in San Francisco with additional offices in New York City, Hong Kong, London, Paris and São Paulo. | Finance |
Healthcare Royalty Management LLC
Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut. | Finance |
The Frankel Group Associates LLC
The Frankel Group Associates LLC Miscellaneous Commercial ServicesCommercial Services The Frankel Group Associates LLC provides strategic management consulting services to the life science industry. The company is headquartered in New York, NY. | Commercial Services |
Longitude Capital Management Co LLC
Longitude Capital Management Co LLC Investment ManagersFinance Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California. | Finance |
Auven Therapeutics Management LLLP
Auven Therapeutics Management LLLP Investment ManagersFinance Founded in 2007 by Stephen Evans-Freke and Peter Corr, Auven Therapeutics Management LLLP is a global private equity firm located in St. Thomas, Virgin Islands. They also have operations in New York City and Europe. The firm was formerly known as Celtic Therapeutics Management, which was the successor firm to Celtic Pharma Management LP. | Finance |
Cydan II, Inc.
Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA. | Health Technology |
Blue Owl Credit Advisors LLC
Blue Owl Credit Advisors LLC Investment ManagersFinance Blue Owl Credit Advisors LLC (Blue Owl Credit Advisors) is a private equity subsidiary of Blue Owl Capital, Inc founded in 2015 by Douglas Ostrover, Marc Lipschultz and Craig W. Packer. The firm headquartered in New York. | Finance |
CrownWheel Partners LLC
CrownWheel Partners LLC Financial ConglomeratesFinance CrownWheel Partners LLC engages in the provision of structure financing solutions with healthcare companies, academic institutions, and inventors. It focuses on the monetization of royalty streams, revenue participation, and purchase of structured debt and equity. The company was founded by Sandip K. Agarwala in 2013 and is headquartered in Greenwich, CT. | Finance |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Health Technology |
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | Commercial Services |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Commercial Services |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Health Technology |